Patient and economic burdens of postherpetic neuralgia in China
- PMID: 31564930
- PMCID: PMC6731977
- DOI: 10.2147/CEOR.S203920
Patient and economic burdens of postherpetic neuralgia in China
Abstract
Background: Little is known about the patient-reported and economic burdens of postherpetic neuralgia (PHN) among China's urban population.
Methods: This noninterventional study was conducted among adults ≥40 years with PHN who were seeking medical care at eight urban hospitals in China. At one study site, patients completed a questionnaire evaluating the patient-reported disease burden (N=185). The questionnaire consisted of validated patient-reported outcomes including the Brief Pain Inventory (BPI), 5-dimension, 3-level EuroQol (EQ-5D-3L), Medical Outcomes Study Sleep Scale, and Work Productivity and Activity Impairment Questionnaire for Specific Health Problems. Questions on non-pharmacologic therapy and out-of-pocket (OOP) expenses were also included. At all study sites, physicians (N=100) completed a structured review of patient charts (N=828), which was used to derive health care resource utilization and associated costs from the societal perspective. Annual costs in Chinese Yuan Renminbi (RMB) for the year 2016 were converted to US dollars (US$).
Results: Patients (N=185, mean age 63.0 years, 53.5% female) reported pain of moderate severity (mean BPI score 4.6); poor sleep quantity (average of 5.3 hrs per night) and quality; and poorer health status on the EQ-5D-3L relative to the general Chinese population. Respondents also reported average annual OOP costs of RMB 16,873 (US$2541) per patient, mainly for prescription PHN medications (RMB 8990 [US$1354]). Substantial work impairment among employed individuals resulted in annual indirect costs of RMB 28,025 (US$4221). In the chart review, physicians reported that patients (N=828) had substantial health resource utilization, especially office visits; 98% had all-cause and 95% had PHN-related office visits. Total annual direct medical costs were RMB 10,002 (US$1507), mostly driven by hospitalizations (RMB 8781 [US$1323]).
Conclusion: In urban China, PHN is associated with a patient-reported burden, affecting sleep, quality-of-life, and daily activities including work impairment, and an economic burden resulting from direct medical costs and indirect costs due to lost productivity. These burdens suggest the need for appropriate prevention and management of PHN.
Keywords: China; EQ-5D; disease burden; health care costs; health-related quality-of-life; postherpetic neuralgia; productivity.
© 2019 Yu et al.
Conflict of interest statement
Marco DiBonaventura (an employee of Kantar Health at the time this study was conducted), Yu-Xuan Chen, Patrick Hlavacek, Markay Hopps, Margarita Udall, Alesia Sadosky, and Joseph C Cappelleri are employees of Pfizer and have stock options in Pfizer. Kristen Concialdi and Ian Kudel are employees of Kantar Health, who were paid consultants to Pfizer in relation to this study. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study.Adv Ther. 2021 Jun;38(6):3325-3341. doi: 10.1007/s12325-021-01717-7. Epub 2021 May 19. Adv Ther. 2021. PMID: 34013498 Free PMC article.
-
The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy.Open Forum Infect Dis. 2019 Jan 12;6(2):ofz007. doi: 10.1093/ofid/ofz007. eCollection 2019 Feb. Open Forum Infect Dis. 2019. PMID: 30793003 Free PMC article.
-
[Survey of economic burden of hepatitis B-related diseases in 12 areas in China].Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Jul 10;38(7):868-876. doi: 10.3760/cma.j.issn.0254-6450.2017.07.005. Zhonghua Liu Xing Bing Xue Za Zhi. 2017. PMID: 28738457 Chinese.
-
Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.Clin Ther. 2006 Nov;28(11):1922-34. doi: 10.1016/j.clinthera.2006.11.017. Clin Ther. 2006. PMID: 17213013
-
A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia.Age Ageing. 2006 Mar;35(2):132-7. doi: 10.1093/ageing/afj048. Epub 2006 Jan 23. Age Ageing. 2006. PMID: 16431855
Cited by
-
A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.Hum Vaccin Immunother. 2024 Dec 31;20(1):2344983. doi: 10.1080/21645515.2024.2344983. Epub 2024 May 20. Hum Vaccin Immunother. 2024. PMID: 38767209 Free PMC article. Review.
-
Exploring the Mechanism of Immediate Analgesia Induced by Tuina Intervention on Minor Chronic Constriction Injury in Rats Using LC-MS.J Pain Res. 2024 Jan 23;17:321-334. doi: 10.2147/JPR.S438682. eCollection 2024. J Pain Res. 2024. PMID: 38283563 Free PMC article.
-
Bidirectional two-sample Mendelian randomization analysis reveals a causal effect of interleukin-18 levels on postherpetic neuralgia risk.Front Immunol. 2023 May 25;14:1183378. doi: 10.3389/fimmu.2023.1183378. eCollection 2023. Front Immunol. 2023. PMID: 37304287 Free PMC article.
-
Lifetime risk of herpes zoster in the population of Beijing, China.Public Health Pract (Oxf). 2023 Jan 10;5:100356. doi: 10.1016/j.puhip.2023.100356. eCollection 2023 Jun. Public Health Pract (Oxf). 2023. PMID: 36968763 Free PMC article.
-
Patterns and Trends in Pharmacological Treatment for Outpatients with Postherpetic Neuralgia in Six Major Areas of China, 2015-2019.Healthcare (Basel). 2023 Mar 6;11(5):764. doi: 10.3390/healthcare11050764. Healthcare (Basel). 2023. PMID: 36900769 Free PMC article.
References
-
- International Association for the Study of Pain. IASP taxonomy. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698. Accessed September5, 2018.
LinkOut - more resources
Full Text Sources